nach oben

Current Fungal Infection Reports

Erschienen in:

09.06.2020 | Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz and M Pereira, Section Editors)

Emerging Fungal Cutaneous Infections in Immunocompromised Patients

verfasst von: Aditya Chandorkar, Jacques Simkins

Erschienen in: Current Fungal Infection Reports | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review summarizes epidemiological risk factors, clinical manifestations, diagnosis, and treatment of common emerging fungal infections that are associated with cutaneous manifestations, in immunocompromised patients including solid organ transplant and hematopoietic cell transplant recipients.

Recent Findings

Immunocompromised patients including transplant recipients are at an increased risk of invasive fungal disease due to emerging fungi, such as mucormycetes and Scedosporium spp. Although cutaneous involvement is common, there is a great degree of variation in clinical manifestations, diagnostic techniques, and more importantly, treatment with antifungals.

Summary

The cutaneous manifestations of emerging fungal pathogens in immunocompromised patients can be localized or part of a disseminated disease. These fungal infections are remarkable for their varying resistance to antifungals. It is essential for clinicians to be knowledgeable about these infections as early treatment might improve outcomes including survival.

Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.PubMed

Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. F1000 Med Rep. 2011;3:14. https://doi.org/10.3410/M3-14.CrossRefPubMedPubMedCentral

Murray PR. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press; 1999. p. 1173.

Crissey JT, Lang H, Parrish LC. Manual of Medical Mycology. Cambridge: Blackwell Scientific; 1995. p. 263.

•• Shoham S, Dominguez EA, AST infectious diseases Community of Practice. Emerging fungal infections in solid organ transplant recipients: guidelines of the American Society of Transplantation infectious diseases Community of Practice. Clin Transpl. 2019;33:e13525 Most recently updated set of guidelines from Transplant Infectious Disease physicians about diagnosis and management of emerging fungal infections in solid organ transplant recipients.

• Castrejón-Pérez AD, Welsh EC, Miranda I, Ocampo-Candiani J, Welsh O. Cutaneous mucormycosis. An Bras Dermatol. 2017;92:304–11 Review summarizing clinical manifestations and diagnosis of cutaneous involvement in mucormycosis.PubMedPubMedCentral

Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin Infect Dis. 2007;44:1089–90.PubMed

Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068–75.PubMed

Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Picardi M, et al. Mucormycosis in hematologic patients. Haematologica. 2004;89:207–14.PubMed

10.

•• Bays DJ, Thompson GR 3rd. Fungal infections of the stem cell transplant recipient and hematologic malignancy patients. Infect Dis Clin N Am. 2019;33:545–66 Updated clinical review of invasive fungal infections as seen in patients with hematological malignancies and hematopoietic transplant recipients.

11.

Devauchelle P, Jeanne M, Fréalle E. Mucormycosis in Burn Patients. J Fungi (Basel). 2019;5:E25.

12.

Warkentien T, Rodriguez C, Lloyd B, Wells J, Weintrob A, Dunne JR, et al. Infectious disease clinical research program trauma infectious disease outcomes study group. Invasive mold infections following combat-related injuries. Clin Infect Dis. 2012;55:1441–9.PubMedPubMedCentral

13.

Neblett-Fanfair R, Benedict K, Bos J, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367:2214–25.PubMed

14.

•• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53 First comprehensive literature review describing epidemiology and outcomes in all reported cases of Mucormycosis since 1885.PubMed

15.

Hata DJ, Buckwalter SP, Pritt BS, Roberts GD, Wengenack NL. Real-time PCR method for detection of Zygomycetes. J Clin Microbiol. 2008;46:2353–8.PubMedPubMedCentral

16.

Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–9.PubMed

17.

Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–37.PubMed

18.

Heath CH, Slavin MA, Sorrell TC, Handke R, Harun A, Phillips M, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect. 2009;15:689–93.PubMed

19.

•• Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–97 Comprehensive review of history, pathogenesis, clinical manifestations, and treatment of different types of invasiveScedosporiuminfections.PubMedPubMedCentral

20.

Rougeron A, Giraud S, Alastruey-Izquierdo A, Cano-Lira J, Rainer J, Mouhajir A, et al. Ecology of Scedosporium species: present knowledge and future research. Mycopathologia. 2018;183:185–200.PubMed

21.

Neofytos D, Fishman J, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12:220–9.PubMed

22.

Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis. 2006;43:1580–4.PubMed

23.

Husain S, Munoz P, Forrest G, Alexander BD, Somani J, Brennan K, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89–99.PubMed

24.

Caston JJ, Linares MJ, Rivero A, Casal M, Torre-Cisneros J. Clinical differences between invasive pulmonary infection by Scedosporium apiospermum and invasive pulmonary aspergillosis. Mycoses. 2011;54:e468–73.PubMed

25.

Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17.PubMed

26.

Miyamoto T, Sasaoka R, Kawaguchi M, Ishioka S, Inoue T, Yamada N, et al. Scedosporium apiospermum skin infection: a case report and review of the literature. J Am Acad Dermatol. 1998;39:498–500.PubMed

27.

Uenotsuchi T, Moroi Y, Urabe K, Tsuji G, Koga T, Matsuda T, et al. Cutaneous Scedosporium apiospermum infection in an immunocompromised patient and a review of the literature. Acta Derm Venereol. 2005;85:156–9.PubMed

28.

Bower CP, Oxley JD, Campbell CK, Archer CB. Cutaneous Scedosporium apiospermum infection in an immunocompromised patient. J Clin Pathol. 1999;52:846–8.PubMedPubMedCentral

29.

Bosma F, Voss A, van Hamersvelt HW, de Sévaux RGL, Biert J, Kullberg BJ, et al. Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clin Microbiol Infect. 2003;9:750–3.PubMed

30.

Gillum PS, Gurswami A, Taira JW. Localized cutaneous infection by Scedosporium prolificans (inflatum). Int J Dermatol. 1997;36:297–9.PubMed

31.

Rüchel R, Margraf S. Rapid microscopical diagnosis of deep-seated mycoses following maceration of fresh specimens and staining with optical brighteners. Mycoses. 1993;36:239–42.PubMed

32.

Idigoras P, Garcia-Arenzana JM, Saenz JR, Pineiro L, Marin J. Isolation of Scedosporium prolificans from the air in the room of a patient with leukemia and disseminated infection with this fungus. Enferm Infecc Microbiol Clin. 2000;18:426–7.PubMed

33.

Ruiz-Díez B, Martín-Díez F, Rodríguez-Tudela JL, Alvárez M, Martínez-Suárez JV. Use of random amplification of polymorphic DNA (RAPD) and PCR-fingerprinting for genotyping a Scedosporium prolificans (inflatum) outbreak in four leukemic patients. Curr Microbiol. 1997;35:186–90.PubMed

34.

Sitterlé E, Giraud S, Leto J. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and accurate identification of Pseudallescheria/Scedosporium species. Clin Microbiol Infect. 2014;20:929–35.PubMed

35.

• McCarthy MW, Katragkou A, Iosifidis E, Roilides E, Walsh TJ. Recent advances in the treatment of Scedosporiosis and Fusariosis. J Fungi (Basel). 2018;4:1–16 Summary of newer diagnostic techniques and updates in management including evidence for newer triazoles.

36.

Rodriguez MM, Calvo E, Serena C, Marine M, Pastor FJ, Guarro J. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53:2153–5.PubMedPubMedCentral

37.

Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 2003;47:106–17.PubMedPubMedCentral

38.

Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH, Lutsar I, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–50.PubMedPubMedCentral

39.

Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev. 1994;7:479–504.PubMedPubMedCentral

40.

Elvers K, Leeming K, Moore C, Lappin-Scott H. Bacterial-fungal biofilms in flowing water photo-processing tanks. J Appl Microbiol. 1998;84:607–18.PubMed

41.

• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis. 2010;50:1091–100 Large nationwide prospective surveillance study with epidemiological information about invasive fungal infections in hematopoietic transplant patients.PubMed

42.

Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38:1237–42.PubMed

43.

Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315–9.PubMed

44.

•• Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis. 2002;35:909–20 Large study with 259 patients describing cutaneous involvement inFusarium, contrasting manifestations in immunocompetent and immunocompromised patients.PubMed

45.

Bodey GP. Dermatologic manifestations of infections in neutropenic patients. Infect Dis Clin North Am. 1994;8:655–75.PubMed

46.

Prins C, Chavaz P, Tamm K, Hauser C. Ecthyma grangrenosum-like lesions: a sign of disseminated Fusarium infection in the neutropenic patient. Clin Exp Dermatol. 1995;20:428–30.PubMed

47.

Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695–704.PubMedPubMedCentral

48.

Ooi SP, Chen TT, Huang TH, Chang HS, Hsieh HY. Granuloma annulare-like skin lesion due to Fusarium roseum: therapy with ketoconazole [letter]. Arch Dermatol. 1987;123:167–8.PubMed

49.

Benjamin RP, Callaway L, Conant NF. Facial granuloma associated with Fusarium infection. Arch Dermatol. 1970;101:598–600.PubMed

50.

Girardi M, Glusac EJ, Imaeda S. Subcutaneous Fusarium foot abscess in a renal transplant patient. Cutis. 1999;63:267–70.PubMed

51.

English MP. Invasion of the skin by filamentous non-dermatophyte fungi. Br J Dermatol. 1968;80:282–6.PubMed

52.

Hennequin C, Ranaivoarimalala C, Chouaki T, Tazerout M, Ancelle T, Cabaud JJ, et al. Comparison of aerobic standard medium with specific fungal medium for detecting Fusarium spp in blood cultures. Eur J Clin Microbiol Infect Dis. 2002;21:748–50.PubMed

53.

Bushelman SJ, Callen JP, Roth DN, Cohen LM. Disseminated Fusarium solani infection. J Am Acad Dermatol. 1995;32:346–51.PubMed

54.

Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205.PubMed

55.

Hue FX, Huerre M, Rouffault MA, de Bievre C. Specific detection of Fusarium species in blood and tissues by a PCR technique. J Clin Microbiol. 1999;37:2434–8.PubMedPubMedCentral

56.

• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006;50:917–21 Results of susceptibility testing for antifungals including triazoles providing useful clinical data for frequently multidrug-resistant filamentous fungi includingFusarium, Scedosporium, andScopulariopsisamong others.PubMedPubMedCentral

57.

Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446–50.PubMedPubMedCentral

58.

Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398–403.PubMed

59.

Cornely OA, Ostrosky-Zeichner L, Rahav G, et al. Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp treated with isavuconazole: experience from the VITAL and SECURE trials. (Abstract M-1760). In: Program and abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2014.

60.

Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis. 2005;40:S401–S8.PubMed

61.

Córdoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents. 2008;31:171–4.PubMed

62.

Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis. 2004;48:69–71.PubMed

63.

De Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of clinical fungi. 2nd ed. Baarn: Centraalbureau Voor Schimmelcultures; 2000. p. 794–809.

64.

• Pastor FJ, Guarro J. Clinical manifestations, treatment, and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006;12:948–60 Comprehensive literature review of 119 cases ofPaecilomyces lilanicusincluding clinical presentations and review of treatment for this frequently multidrug resistant fungus.PubMed

65.

Itin PH, Frei R, Lautenschlager S, et al. Cutaneous manifestations of Paecilomyces lilacinus infection induced by a contaminated skin lotion in patients who are severely immunosuppressed. J Am Acad Dermatol. 1998;39:401–9.PubMed

66.

Jade KB, Lyons MF, Gnann JW. Paecilomyces lilacinus cellulitis in an immunocompromised patient. Arch Dermatol. 1986;122:1169–70.PubMed

67.

Summerbell R. Ascomycetes, Aspergillus, Fusarium, Sporothrix, Piedraia, and their relatives. In: Howard DH, editor. Pathogenic fungi in humans and animals. 2nd ed. New York: Dekker; 2003. p. 237–498.

68.

Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol. 1998;109:45–54.PubMed

69.

Aguilar C, Pujol I, Sala J, Guarro J. Antifungal susceptibilities of Paecilomyces species. Antimicrob Agents Chemother. 1998;42:1601–4.PubMedPubMedCentral

70.

Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon moulds: NCCLS collaborative study. J Clin Microbiol. 2002;40:3776–81.PubMedPubMedCentral

71.

Feldman R, Cockerham L, Buchan BW, Lu Z, Huang AM. Treatment of Paecilomyces variotii pneumonia with posaconazole: case report and literature review. Mycoses. 2016;59:746–50.PubMed

72.

Yehia M, Thomas M, Pilmore H, et al. Subcutaneous black fungus (phaeohyphomycosis) infection in renal transplant recipients: three cases. Transplantation. 2004;15:140–2.

73.

Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev. 2010;23:884–928.PubMedPubMedCentral

74.

Caviedes MP, Torre AC, Eliceche ML, Valdivia Monteros DC, Volonteri VI, Galimberti RL. Cutaneous phaeohyphomycosis. Int J Dermatol. 2017;56:415–20.PubMed

75.

• McCarty TP, Baddley JW, Walsh TJ, et al. Phaeohyphomycosis in transplant recipients: results from the transplant associated infection surveillance network (TRANSNET). Med Mycol. 2015;53:440–6 Review of 56 clinical cases in literature including both solid organ transplants and hematopoietic cell transplants providing useful information about cutaneous presentations and antifungal treatment used in clinical cases.PubMed

76.

Shoham S, Marr KA. Invasive fungal infections in solid organ transplant recipients. Future Microbiol. 2012;7:639–55.PubMedPubMedCentral

77.

Boyce RD, Deziel PJ, Otley CC, Wilhelm MP, Eid AJ, Wengenack NL, et al. Phaeohyphomycosis due to Alternaria species in transplant recipients. Transpl Infect Dis. 2010;12:242–50.PubMed

78.

Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis. 2009;48:1033–41.PubMed

79.

Essabbah N, Gorsane I, Youssef M, Hadhri R, Aloui S, Gorcii M, et al. Cutaneous alternariosis in a renal transplant recipient. Cutis. 2014;93:237–40.PubMed

80.

Cunhaa D, Amaroa C, Vieiraa MR, et al. Phaeohyphomycosis caused by Alternaria infectoria presenting as multiple vegetating lesions in a renal transplant patient. Rev Iberoam Micol. 2012;29:44–6.

81.

Rinaldi MG. Phaeohyphomycosis. Dermatol Clin. 1996;14:147–53.PubMed

82.

Cuétara MS, Alhambra A, Moragues MD, et al. Detection of (1-->3)-beta-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven invasive fungal diseases or with an unusual clinical presentation. Clin Vaccine Immunol. 2009;16:423–6.PubMedPubMedCentral

83.

Hsu C, Chang S, Lee P, et al. Cutaneous alternariosis in a renal transplant recipient: a case report and literature review. Asian J Surg. 2015;38:47–57.PubMed

84.

Revankar SG, Baddley JW, Chen SC, et al. A mycoses study group international prospective study of phaeohyphomycosis: an analysis of 99 proven/probable cases. Open Forum Infect Dis. 2017;4(4):ofx200.PubMedPubMedCentral

Titel: Emerging Fungal Cutaneous Infections in Immunocompromised Patients
verfasst von: Aditya Chandorkar
Jacques Simkins
Publikationsdatum: 09.06.2020
Verlag: Springer US
Erschienen in: Current Fungal Infection Reports / Ausgabe 3/2020
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-020-00395-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Pharmacokinetics and Pharmacodynamics of Antifungal Agents in Neonates and Children

Conidiobolomycosis in Pediatric Patients

Review of the Current Management of Urinary Tract Infections due to Fluconazole-Resistant and Non-Albicans Candida Species

Cryptococcosis in Liver Transplant Candidates and Recipients

Invasive Phaeohyphomycosis in Immunocompetent Hosts